News & Updates

Blood pressure variability implicated in dementia risk
Blood pressure variability implicated in dementia risk
01 Oct 2021
DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
28 Sep 2021 byJairia Dela Cruz

In the treatment of patients with type 2 diabetes mellitus and hypertension, switching from a dipeptidyl peptidase-4 (DPP-4) inhibitor to the sodium-glucose cotransporter-2 (SGLT2) inhibitor luseogliflozin appears to have favourable effects on blood pressure (BP), circadian rhythm, and night-time systolic BP (SBP) and pulse rate (PR), according to data from the open-label LUNA trial.

DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
28 Sep 2021